Osteonecrosis of Maxilla Secondary to Bisphosphonate Therapy: A Case Report

被引：4

作者：

Kolur T. ^{[1
]}

Nair S.C. ^{[1
]}

Kumar B. ^{[1
]}

机构：

[1] Bhagwan Mahaveer Jain Hospital, Bangalore, Karnataka

来源：

Journal of Maxillofacial and Oral Surgery | 2015年 / 14卷 / Suppl 1期

关键词：

Bisphosphonate; Maxilla; Osteonecrosis;

D O I：

10.1007/s12663-011-0284-z

中图分类号：

学科分类号：

摘要：

Bisphosphonate chemotherapy is commonly used in the treatment of bone diseases such as osteoporosis, Paget disease, and multiple myeloma and to limit bone pain and hypercalcemia associated with malignant metastatic bone lesions. The introduction of bisphosphonate therapy has improved the quality of life in a vast majority of patients. However, since 2003 a growing number of reports have described necrotic bone lesions (bisphosphonate—associated Osteonecrosis of the jaw [BR-ONJ]) a bone lesion affecting maxillofacial bones in patients who have received high dosage chemotherapy with intravenous bisphosphonate therapy especially when the patient undergoes subsequent dental procedures. Sequential removal of sequestra as required seems to be the current conservative approach, but if large-volume debridement becomes necessary, removal of the bone sequestrum with minimal epithelial manipulation associated with topical and systemic antibiotics seem to be the treatment modality of choice. In our case, surgical salvage was performed successfully for BR-ONJ. Our experience indicates that with appropriate technique, primary surgical treatment may offer benefit to selected patients with BR-ONJ. © 2011, Association of Oral and Maxillofacial Surgeons of India.

引用

页码：52 / 56

页数：4

共 18 条

[1]

Woo S.B., Hellstein J.W., Kalmar J.R., Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws, Ann Intern Med, 144, 10, pp. 753-761, (2006)

[2]

Ruggiero S.L., Fantasia J., Carlson E., Bisphosphonate related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 102, pp. 433-440, (2006)

[3]

Marx R.E., Sawatari Y., Fortin M., Broumand V., Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment, J Oral Maxillofac Surg, 63, pp. 1567-1575, (2005)

[4]

Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., Mangood R.G., Et al., Novel Insights into Actions of Bisphosphonates on Bone Differences in Interactions with Hydroxyapatite, (2005)

[5]

Vaananen K., Mechanism of osteoclast mediated bone resorption—rationale for the design of new therapeutics, Adv Drug Deliv Rev, 57, pp. 959-971, (2005)

[6]

Wang J., Goodger N.M., Pogrel M.A., Osteonecrosis of the jaws associated with cancer chemotherapy, J Oral Maxillofac Surg, 61, pp. 1104-1107, (2003)

[7]

Marx R.E., Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws a growing epidemic, J Oral Maxillofac Surg, 61, pp. 1115-1117, (2003)

[8]

Miglioratti C.A., Bisphosphonates and oral cavity avascular bone necrosis, J Clin Oncol, 21, pp. 4253-4254, (2003)

[9]

Hellstein J.W., Marek C.L., Pharm B.S., Bisphosphonate osteochemonecrosis (bis-phossy jaw) is this phossy jaw of the 21st century?, J Oral Maxillofac Surg, 63, pp. 682-689, (2005)

[10]

Hellstein J., Fielding C., Bisphosphonate osteochemonecrosis clinical findings and treatment theories may relate to a possible analogy with “phossy” jaw, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 100, pp. 189-190, (2005)

← 1 2 →